ScRNA-Seq of MC38 CD45+ Cells treated with EZH2 inhibitor PF-06821497

ABSTRACT: The purpose of this study was to determine the effect of EZH2 inhibitor (EZH2i) PF-06821497 on CD45+ cells isolated from MC38 tumors at day 17 post implantation. Mice were either treated for 7 days prior to endpoint or 16 days prior to endpoint with the EZH2i or with vehicle control. CD45+ cells were isolated and scRNA-Seq was performed on cells

ORGANISM(S): Mus musculus

PROVIDER: GSE188473 | GEO | 2021/11/10

REPOSITORIES: GEO